An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. (Q53675802)
Jump to navigation
Jump to search
scientific article published on 15 October 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. |
scientific article published on 15 October 2014 |
Statements
An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. (English)
Cornelius F Waller
Yaroslav Shparyk
Jeffrey P Hodge
Anne Freeman
Brian Huber
Ronald Lieberman
Mark J Shelton
Harish Dave
15 October 2014
16
2
92-99